Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidance.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) are increasingly used to treat various cancers. Their use may result in immune-related adverse events, including psoriasis. When managing psoriasis, induced or exacerbated by an ICI, there are concerns regarding immunosuppression from systemic agents for the treatment of psoriasis (saPs) and the potential impact on ICI efficacy. No direct, high-level evidence exists to address these concerns.

Objective

To address clinically relevant questions regarding the management of ICI-mediated psoriasis (ICI-Ps) with saPs.

Methods

We convened a multidisciplinary panel of 15 international specialists in dermatology, oncology, immunology, and rheumatology. A Delphi process defined clinical concerns related to the systemic treatment of

SUBMITTER: Papp KA 

PROVIDER: S-EPMC12553135 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature